Kylie Kattelus
Family · Owosso, MINPI 1467044941
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.6%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 60.1% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $6,904, more than ten times the $183 reported in 2021. Among family clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 458 payments — averaging $34.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Lundbeck LLC$2K
- Lilly USA, LLC$647
- Pfizer$641
- Teva Pharmaceuticals USA, Inc.$391
- Eisai Inc.$302
- plus $2K from 28 others
Across 13 payments — averaging $147.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$2K
What the payments were for
- Consulting fees$7955%
- Speaking & faculty fees$7,45448%
- Food & beverage$7,31047%
- Education$1081%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 142 | $9,422 |
| Lundbeck LLC | 65 | $1,823 |
| Lilly USA, LLC | 45 | $647 |
| Pfizer | 51 | $641 |
| Teva Pharmaceuticals USA, Inc. | 10 | $391 |
| Eisai Inc. | 12 | $302 |
| Axsome Therapeutics, Inc. | 9 | $244 |
| Amgen | 23 | $230 |
| UCB, Inc. | 9 | $206 |
| Impel Pharmaceuticals Inc. | 11 | $204 |
| Sumitomo Pharma America, Inc. | 9 | $172 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $153 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $144 |
| Neurelis, Inc. | 7 | $127 |
| SK Life Science, Inc. | 5 | $117 |
| Jazz Pharmaceuticals Inc. | 4 | $100 |
| Otsuka America Pharmaceutical, Inc. | 5 | $90 |
| Averitas Pharma Inc. | 5 | $88 |
| Amneal Pharmaceuticals LLC | 3 | $73 |
| Scilex Pharmaceuticals Inc. | 3 | $68 |
| Argenx US, Inc. | 3 | $68 |
| Acorda Therapeutics, Inc | 3 | $62 |
| Sanofi | 2 | $42 |
| AstraZeneca | 2 | $37 |
| CSL Behring | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 2 | $31 |
| Neurocrine Biosciences, Inc. | 1 | $29 |
| Biogen | 1 | $23 |
| GRT US Holding, Inc. | 1 | $20 |
| Sage Therapeutics, LLC | 1 | $18 |
| Aucta Pharmaceuticals, Inc. | 1 | $17 |
| Avion Pharmaceuticals | 1 | $16 |
| Corium, LLC | 1 | $16 |
| Sarepta Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QULIPTA$7,555
- UBRELVY$1,776
- VYEPTI$896
- NURTEC ODT$135
- Austedo XR$113
- AJOVY$110
- Trudhesa$108
- Symbravo$106
How this compares
$15,666 in reported general payments places this provider in the 95th percentile of 3,657 family providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 78 | $115,369 |
| Nurtec OdtRimegepant Sulfate | 61 | $81,733 |
| Emgality PenGalcanezumab-Gnlm | 105 | $80,673 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 70 | $61,572 |
| Aimovig AutoinjectorErenumab-Aooe | 58 | $49,350 |
| QuliptaAtogepant | 38 | $41,398 |
| Emgality SyringeGalcanezumab-Gnlm | 28 | $19,117 |
| Ajovy SyringeFremanezumab-Vfrm | 14 | $10,844 |
| Sumatriptan Succinate | 49 | $3,701 |
| Gabapentin | 115 | $2,542 |
| Duloxetine Hcl | 46 | $1,487 |
| Lamotrigine | 79 | $1,187 |
| Topiramate | 77 | $1,152 |
| Memantine Hcl | 55 | $854 |
| Pregabalin | 19 | $829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $9,422 | $156,768116 claims |
| PfizerNurtec Odt | $641 | $81,73361 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,657 family providers in Michigan.
Other family in Owosso
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.